CompletedPhase 1

Single Ascending Dose Study of SRA-444 in Healthy Subjects

Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SRA-444 Administered Orally to Healthy Adult Subjects

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Asset

SRA-444

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Alzheimer’s disease

Key I/E criteria

•Age 18-50•Male

Primary endpoint

•Assessment of the safety and tolerability of SRA-444

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID3197A1-100

NCT IDNCT00452504

Timeline

Milestones

Study start2007-02 (month precision)

Study first posted2007-03-27estimated

Study completion2007-06actual (month precision)

Last update posted2007-12-05estimated

Assets

Drug assets

SRA-444

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age18 Years

Maximum age50 Years

SexMale

Healthy volunteersAccepted

Inclusion criteria

•Healthy men or women of nonchildbearing potential aged 18 to 50 years,

•Body mass index in the range of 18 to 30 kg/m2 and body weight ≥50 kg

Exclusion criteria

•Family history of sudden death and/or QT prolongation.

•An automatic ECG corrected QT (QTc) interval reading at screening >450 ms and >470 ms for male and female subjects, respectively.

•Sinus bradycardia at screening, defined as a resting heart rate ≤45 bpm. Resting supine blood pressure at screening <110 mm Hg (systolic) and/or <60 mm Hg (diastolic).

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

1 endpoint

Primary/protocol endpoint

Assessment of the safety and tolerability of SRA-444

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.